Blinatumomab [BLI2]

The treatment of relapsed/refractory Philadelphia negative B-precursor acute lymphoblastic leukaemia in CHILD patients

1. An application is being made and the first cycle of systemic anti-cancer therapy with blinatumomab will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.
2. The patient is a child and ONE of the following applies: OPTION 1 - The patient is post pubescent. OPTION 2 - The patient is pre pubescent Please choose correct option

• Option A
• Option B NB. There is a separate Blueteq form to be used for blinatumomab in this indication in adults.

3. The patient has relapsed or refractory Philadelphia negative acute lymphoblastic leukaemia (ALL).
4. The patient has been previously treated with intensive combination chemotherapy as initial treatment with or without subsequent salvage therapy.
5. The first cycle of blinatumomab will only be requested by, prescribed, and commenced in Principal Treatment Centres (PTCs). Subsequent cycles (including the latter parts of the first 28-day treatment cycle) of blinatumomab may be administered at the PTC or in partnership with enhanced POSCUs under the direction of the PTCs and in agreement with relevant Operational Delivery Networks
6. The use of the blinatumomab has been discussed at a multidisciplinary team (MDT) meeting which must include at least two consultants in the subspecialty with active and credible expertise in the relevant field of whom at least one must be a consultant paediatrician. The MDT should include a paediatric pharmacist and other professional groups appropriate to the disease area.
7. The patient has a Karnofsky/Lansky performance score of 60 or more.
8. A maximum of 5 cycles of treatment with blinatumomab will be administered.
9. The use of blinatumomab in this indication is exempt from the NHS England Treatment Break policy.
10. Relevant Trust policy regarding off-label treatments will be followed for children less than 1 year of age, as blinatumomab is not licensed in this age group.
11. Blinatumomab should otherwise be used as set out in its Summary of Product Characteristics (SPC).

NHS funded From: 26 September 2017

Additional information

Form version: -

CDF Managed Access: NA

NICE Technology Appraisal: TA450 (27 April 2017)

Current Form Version

Note

The data on this page was produced using version 1.377 of the CDF list, downloaded from NHS England’s website on 18 November 2025 at 09:00.

If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.

Older Form Versions

There are previous versions of this form. These may not all be available on this site.

• BLI2_prior_to_cdf_1.361
• BLI2_prior_to_cdf_1.363
• BLI2_prior_to_cdf_1.377